beta-Catenin regulates tumor-derived PD-L1

In this issue of JEM, Du et al. (https://doi.org/10.1084/jem.20191115) report that enhancement of the beta-catenin signaling by Wnt or EGF treatment increases the expression of PD-L1 in an AKT and beta-catenin-dependent manner, and blocking the AKT pathway synergizes with anti-PD-1 in a glioblastoma model.